Publicacións nas que colabora con Eva Lumbreras González (22)

2022

  1. 25-Hydroxyvitamin D Serum Levels Linked to Single Nucleotide Polymorphisms (SNPs) (rs2228570, rs2282679, rs10741657) in Skeletal Muscle Aging in Institutionalized Elderly Men Not Supplemented with Vitamin D

    International Journal of Molecular Sciences, Vol. 23, Núm. 19

  2. ALL-268 Genetic Classification of B-Cell Precursor Adult Acute Lymphoblastic Leukemia Patients Enrolled in LAL19 Trial from the Pethema Group: Response to Treatment and Survival

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S199

2021

  1. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients

    Annals of Hematology, Vol. 100, Núm. 8, pp. 1995-2004

  2. Co-occurrence of cohesin complex and Ras signaling mutations during progression from myelodysplastic syndromes to secondary acute myeloid leukemia

    Haematologica, Vol. 106, Núm. 8, pp. 2215-2223

2020

  1. Comprehensive custom ngs panel validation for the improvement of the stratification of b-acute lymphoblastic leukemia patients

    Journal of Personalized Medicine, Vol. 10, Núm. 3, pp. 1-21

  2. Genome-wide transcriptomics leads to the identification of deregulated genes after deferasirox therapy in low-risk MDS patients

    Pharmacogenomics Journal, Vol. 20, Núm. 5, pp. 664-671

  3. Machine learning applied to gene expression analysis of T-lymphocytes in patients with cGVHD

    Bone Marrow Transplantation

2019

  1. Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation

    Annals of Hematology, Vol. 98, Núm. 9, pp. 2151-2162

  2. Redefining synchronous colorectal cancers based on tumor clonality

    International Journal of Cancer, Vol. 144, Núm. 7, pp. 1596-1608

2018

  1. Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia

    Leukemia and Lymphoma, Vol. 59, Núm. 5, pp. 1095-1104

2016

  1. MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion

    Leukemia Research, Vol. 46, pp. 30-36

  2. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab

    British journal of haematology, Vol. 172, Núm. 3, pp. 428-438

2015

  1. Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations

    British Journal of Haematology

  2. Fluorescence in situ hybridization analysis does not increase detection rate for trisomy 8 in chronic myelomonocytic leukemia

    Leukemia and Lymphoma

2013

  1. Alteration in Endoglin-Related Angiogenesis in Refractory Cytopenia with Multilineage Dysplasia

    PLoS ONE, Vol. 8, Núm. 1

2012

  1. Expression of VAV1 in the tumour microenvironment of glioblastoma multiforme

    Journal of Neuro-Oncology, Vol. 110, Núm. 1, pp. 69-77

  2. Imatinib therapy of chronic myeloid leukemia restores the expression levels of key genes for DNA damage and cell-cycle progression

    Pharmacogenetics and Genomics, Vol. 22, Núm. 5, pp. 381-388

  3. Integration of global spectral karyotyping, CGH arrays, and expression arrays reveals important genes in the pathogenesis of glioblastoma multiforme

    Annals of Surgical Oncology, Vol. 19, Núm. 7, pp. 2367-2379

2011

  1. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

    Haematologica, Vol. 96, Núm. 10, pp. 1448-1456

2009

  1. Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response

    Leukemia Research, Vol. 33, Núm. 1, pp. 170-173